PDS Biotechnology Q1 Loss Widens

PDS Biotechnology Corp. (PDSB), a clinical-stage immunotherapy company, Monday, reported a wider loss for the first quarter, particularly impacted by personnel, clinical studies, medical affairs, and manufacturing expenses.

Related Keywords

, Thomson Reuters , Biotechnology Corp , Loss Widens In Q1 , Pds Biotechnology Corp , Linical Stage Immunotherapy Company ,